To spark cancer discoveries, several Big Pharma companies are sharing idle clinical trial data

Featured Story

To spark cancer discoveries, several Big Pharma companies are sharing idle clinical trial data

April 8, 2014 7:00 am by | 1 Comments

Big Pharma spends billions of dollars each year researching, developing and testing new treatments for cancer. In the meantime, it’s also collecting millions of data points that figuratively sit on…


Glenmark receives $5 million milestone payment from Sanofi

Glenmark receives $5 million milestone payment from Sanofi

April 15, 2014 3:53 am by | 0 Comments

MUMBAI — Drug maker Glenmark Pharmaceuticals Ltd said on Tuesday that its new drug candidate for the treatment of autoimmune disorder has achieved another milestone towards final stage of discovery….


Two guilty of insider trading in Sanofi deal

Two guilty of insider trading in Sanofi deal

March 8, 2014 4:07 am by | 0 Comments

A jury found two brothers guilty of using insider information to make an illicit $50,000 profit on the stock market in at least the eighth insider trading prosecution related to…



Sanofi sues Glenmark over generic filing on cardiac drug

Sanofi sues Glenmark over generic filing on cardiac drug

March 6, 2014 4:02 am by | 0 Comments

MUMBAI — Sanofi SA has sued Glenmark Pharmaceuticals Ltd in a US court after the Indian company filed an application with the US Food and Drug Administration (FDA) seeking marketing…


Merck latest drugmaker to look for copy Sanofi’s diabetes drug Lantus

Merck latest drugmaker to look for copy Sanofi’s diabetes drug Lantus

February 10, 2014 12:16 pm by | 0 Comments

(Reuters) – U.S. drugmaker Merck & Co has joined the race to make a cut-price copy of Sanofi’s top-selling insulin treatment Lantus, increasing the long-term threat to the French company’s…


10 rival drug companies working together to find new drugs quicker

10 rival drug companies working together to find new drugs quicker

February 4, 2014 2:34 am by | 0 Comments

Feb 4 (Reuters) – Ten big rival drug companies have formed a pact to cooperate on a government-backed effort to accelerate the discovery of new drugs, the Wall Street Journal…


Sanofi buying percentage of Alnylam for $700 M to expand rare genetic disease drugs

Sanofi buying percentage of Alnylam for $700 M to expand rare genetic disease drugs

January 13, 2014 12:00 am by | 0 Comments

Jan 13 (Reuters) – French drugmaker Sanofi will buy a 12 percent stake in Alnylam Pharmaceuticals Inc for $700 million and deepen their partnership to develop genetic disease drugs. The…


Sanofi plans to appeal U.S. rejection of its MS treatment Lemtrada

Sanofi plans to appeal U.S. rejection of its MS treatment Lemtrada

December 30, 2013 1:19 am by | 0 Comments

PARIS (Reuters) – Sanofi said its Lemtrada multiple sclerosis treatment failed to win approval from U.S. regulators to launch in the world’s biggest drug market.
The French firm said it planned to appeal the decision.
The Food and Drug Administration (…



U.S. lawfirm launching class action suit over multiple sclerosis drug Lemtrada

U.S. lawfirm launching class action suit over multiple sclerosis drug Lemtrada

December 20, 2013 10:30 am by | 0 Comments

PARIS, Dec 20 (Reuters) – A U.S. law firm is launching a class action against France’s Sanofi over what it calls misleading statements on the safety and efficacy of its…


Sanofi using ACC registry to find patients for new cholesterol treatment clinical trial

Sanofi using ACC registry to find patients for new cholesterol treatment clinical trial

December 19, 2013 3:46 am by | 0 Comments

PARIS (Reuters) – French drug maker Sanofi and its U.S. partner Regeneron are collaborating with the American College of Cardiology (ACC) to identify patients for clinical trials on alirocumab, their…


Sanofi Gaucher disease treatment pill application gets priority FDA review

Sanofi Gaucher disease treatment pill application gets priority FDA review

December 11, 2013 2:26 am by | 0 Comments

PARIS (Reuters) – French drugmaker Sanofi said U.S. authorities had decided to carry out a priority review of its experimental pill for patients with Gaucher disease. The Food and Drug…


Sanofi’s new long-acting insulin better at controlling blood sugar lows

Sanofi’s new long-acting insulin better at controlling blood sugar lows

December 3, 2013 1:05 am by | 0 Comments

PARIS (Reuters) – An improved version of Sanofi’s diabetes drug Lantus is better than the old one at controlling blood sugar levels and comes with fewer hypoglycemic events, new late-stage…


Rare late-stage bone marrow cancer treatment drug unsafe, ditched by Sanofi

Rare late-stage bone marrow cancer treatment drug unsafe, ditched by Sanofi

November 18, 2013 2:55 am by | 0 Comments

PARIS (Reuters) – Sanofi has halted all clinical trials and cancelled plans to seek regulatory approval of fedratinib, a drug in late-stage development against rare bone marrow cancers, due to safety concerns.
The decision follows recent reports of cas…


Tech ‘accelerator’ looks to drive drugs to market

Tech ‘accelerator’ looks to drive drugs to market

November 13, 2013 4:20 am by | 0 Comments

An Oro Valley company is working to move promising drug discoveries from the lab to the medical marketplace. But Actus Biotechnologies isn’t working with technologies developed at the University of…


Regeneron, Sanofi drug cuts cholesterol in half in late-stage trial

Regeneron, Sanofi drug cuts cholesterol in half in late-stage trial

October 16, 2013 1:04 am by | 0 Comments

(Reuters) – A new type of cholesterol drug being developed by Regeneron Pharmaceuticals Inc and Sanofi SA, when used by itself, cut levels of “bad” LDL cholesterol almost in half in the first of a dozen late-stage trials of the injectable medicine.
Th…


Sanofi’s CEO says pharma industry should support China’s efforts to curb corruption

Sanofi’s CEO says pharma industry should support China’s efforts to curb corruption

September 30, 2013 7:13 am by | 0 Comments

MUMBAI (Reuters) – The pharmaceutical industry should support the Chinese government’s efforts to curb corruption, French drugmaker Sanofi’s Chief Executive Chris Viehbacher said on Monday.
A crackdown on corruption in China’s pharmaceutical sector has…